Business Insider examines the federal government’s anticipated move to reschedule marijuana from Schedule I to Schedule III under the Controlled Substances Act—and which publicly traded cannabis companies are best positioned to benefit from the regulatory shift.
The analysis draws on expert commentary from cannabis industry veterans, including SIVA’s Avis Bulbulyan, to assess how rescheduling would affect taxation, banking access, and competitive dynamics across the sector.
WE DO NOT OWN THIS CONTENT – IT WAS COPIED FROM Business Insider